Circulating MicroRNA‐122 signature in nonalcoholic fatty liver disease and cardiovascular disease: A new endocrine system in metabolic syndrome
Carlos J. Pirola, Tomas Fernández Gianotti, Gustavo O. Castaño, Silvia Sookoian – 30 October 2012
Carlos J. Pirola, Tomas Fernández Gianotti, Gustavo O. Castaño, Silvia Sookoian – 30 October 2012
Domenico Sansonno, Sabino Russi, Vincenza Conteduca, Loredana Sansonno – 30 October 2012
Xiaolei Shi, Viviana Moroso, Herold J. Metselaar, Jaap Kwekkeboom – 30 October 2012
Lauren E. Holz, Joo Chun Yoon, Sukanya Raghuraman, Susan Moir, Michael C. Sneller, Barbara Rehermann – 30 October 2012
Hung‐Chih Yang, Chi‐Ling Chen, Yueh‐Chi Shen, Cheng‐Yuan Peng, Chun‐Jen Liu, Tai‐Chung Tseng, Tung‐Hung Su, Wan‐Long Chuang, Ming‐Lung Yu, Chia‐Yen Dai, Chen‐Hua Liu, Pei‐Jer Chen, Ding‐Shinn Chen, Jia‐Horng Kao – 30 October 2012 – Precore (PC) (G1896A) and basal core promoter (BCP) (A1762T/G1764A) mutations of the hepatitis B virus (HBV) genome often emerge in chronic hepatitis B (CHB) patients. Their roles in hepatitis B e antigen (HBeAg) seroconversion induced by interferon (IFN) therapy remain controversial, partly because quantitative analysis for these mutants is lacking.
Xiao Qi Wang, Cindy K.Y. Cheung, Chung Mau Lo – 30 October 2012
Zhigang Tian, Yongyan Chen, Bin Gao – 30 October 2012 – Natural killer (NK) cells are enriched in lymphocytes within the liver and have unique phenotypic features and functional properties, including tumor necrosis factor–related apoptosis‐inducing ligand–‐dependent cytotoxicity and specific cytokine profiles.
Zhigang Tian, Yongyan Chen, Bin Gao – 30 October 2012 – Natural killer (NK) cells are enriched in lymphocytes within the liver and have unique phenotypic features and functional properties, including tumor necrosis factor–related apoptosis‐inducing ligand–‐dependent cytotoxicity and specific cytokine profiles.
Shmuel Shoham – 29 October 2012
Silja Kosola, Hanna Lampela, Hannu Jalanko, Heikki Mäkisalo, Jouko Lohi, Johanna Arola, Mikko P. Pakarinen – 29 October 2012 – Controversy remains about the role of protocol liver biopsy for symptom‐free recipients and about the long‐term use of low‐dose steroids after pediatric liver transplantation (LT). We conducted a national cross‐sectional study of pediatric recipients who underwent LT between 1987 and 2007.